Literature DB >> 17449802

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.

Kais Hussein, Oliver Bock, Anna Seegers, Michael Flasshove, Felicitas Henneke, Guntram Buesche, Hans Heinrich Kreipe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17449802     DOI： 10.1182/blood-2006-12-061135

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  28 in total

1.  Competing cell clones in myeloproliferative neoplasm.

Authors:  Aref Al-Kali; Srdan Verstovsek; Hagop Kantarjian; Rajyalakshmi Luthra; Jorge Cortes
Journal:  Blood       Date:  2010-12-02       Impact factor: 22.113

2.  Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.

Authors:  Monika Ribeiro Mello de Conchon; Juliana Lima Costa; Mafalda Megumi Yoshinaga Novaes; Pedro Enrique Dorlhiac-Llacer; Dalton de Alencar Fischer Chamone; Israel Bendit
Journal:  Int J Hematol       Date:  2008-07-16       Impact factor: 2.490

3.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

Review 4.  [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].

Authors:  K Hussein; G Büsche; J Schlue; U Lehmann; H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

5.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

6.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

7.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

8.  Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Authors:  Yoo Jin Lee; Joon Ho Moon; Ho Cheol Shin; Jong Won Seo; Seo Ae Han; Sang Kyeong Seo; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

9.  Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.

Authors:  Weiyi Xu; Baode Chen; Xiangmin Tong
Journal:  Int J Hematol       Date:  2013-11-30       Impact factor: 2.490

10.  Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.

Authors:  Leonardo Boiocchi; Umberto Gianelli; Alessandra Iurlo; Falko Fend; Irina Bonzheim; Daniele Cattaneo; Daniel M Knowles; Attilio Orazi
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.